Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease (EMPA-PD)
End Stage Renal Disease on Dialysis
About this trial
This is an interventional other trial for End Stage Renal Disease on Dialysis focused on measuring Peritoneal dialysis
Eligibility Criteria
Inclusion Criteria Patients actively undergoing PD with a reliably functioning PD catheter Stable peritoneal dialysis prescription Chronic loop diuretic usage (at Yale, essentially all patients that make urine are on chronic loop diuretics) PD vintage > 3 months 24 Hour urine output >400 ml Age >18 years of age Exclusion Criteria: History of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months Use of an SGLT2 inhibitor within the prior 30 days 1 or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter Anemia with hemoglobin <8g/dL Inability to give written informed consent or follow study protocol
Sites / Locations
- Yale UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Empagliflozin or Placebo in Acute
Empagliflozin in Chronic
Acute phase: Participants will receive 25 mg empagliflozin once on Day 0 or Day 7. Participants receive empaglifozin or placebo on Day 0. On Day 7, they will be crossed over to the alternate treatment.
Chronic phase: On day 8, all participants will receive 10 mg empagliflozin 10 mg x 8 weeks